Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 1;1(5):e27463.
doi: 10.4161/tisb.27463. Epub 2013 Dec 10.

NFkB and Nrf2 in esophageal epithelial barrier function

Hao Chen  1 , Yu Fang  2 , Wenbo Li  3 , Roy C Orlando  4 , Nicholas Shaheen  4 , Xiaoxin Luke Chen  5
Affiliations

NFkB and Nrf2 in esophageal epithelial barrier function

Hao Chen et al. Tissue Barriers. .

Abstract

The stratified squamous epithelium of the esophagus forms a tight protective barrier. Defects of the barrier function contribute to gastroesophageal reflux disease (GERD), which is manifested as damage to the esophageal epithelium due to exposure to the gastrointestinal refluxate. In this review, we discuss the involvement of NFkB and Nrf2 in esophageal epithelial barrier function. Understanding these molecular pathways in the esophagus may help us develop therapeutic strategies to improve clinical outcomes in patients with GERD.

Keywords: GERD; NFkB; Nrf2; esophageal barrier; esophageal epithelial barrier; esophageal epithelium; reflux disease; tight junction.

PubMed Disclaimer

Figures

None
Figure 1. NFkB and Nrf2 regulate esophageal barrier function during gastresophageal reflux. This mechanistic model implies that NFkB inhibitor and Nrf2 activator can be potentially used for GERD therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Armstrong D, Sifrim D. New pharmacologic approaches in gastroesophageal reflux disease. Gastroenterol Clin North Am. 2010;39:393–418. doi: 10.1016/j.gtc.2010.08.019. - DOI - PubMed
    1. Bateman DN, Colin-Jones D, Hartz S, Langman M, Logan RF, Mant J, Murphy M, Paterson KR, Rowsell R, Thomas S, et al. SURVEIL (Study of Undetected Reactions, Vigilance Enquiry into Links) Group Mortality study of 18 000 patients treated with omeprazole. Gut. 2003;52:942–6. doi: 10.1136/gut.52.7.942. - DOI - PMC - PubMed
    1. Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol. 2010;26:367–78. doi: 10.1097/MOG.0b013e32833ae2be. - DOI - PubMed
    1. Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, Varro A, Dimaline R. Gastrin induces proliferation in Barrett’s metaplasia through activation of the CCK2 receptor. Gastroenterology. 2003;124:615–25. doi: 10.1053/gast.2003.50091. - DOI - PubMed
    1. Hayashi H, Shimamoto K, Taniai E, Ishii Y, Morita R, Suzuki K, Shibutani M, Mitsumori K. Liver tumor promoting effect of omeprazole in rats and its possible mechanism of action. J Toxicol Sci. 2012;37:491–501. doi: 10.2131/jts.37.491. - DOI - PubMed